The Laryngoscope · 2014
Arterial chemoradiotherapy for carcinomas of the external auditory canal and middle ear.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fujiwara Masayuki, Yamamoto Satoshi, Doi Hiroshi, Takada Yasuhiro, Odawara Soichi, Niwa Yasue, Ishikura Reiichi, Kamikonya Norihiko, Terada Tomonori, Uwa Nobuhiro, Sagawa Kosuke, Hirota Shozo
Аннотация
OBJECTIVES/HYPOTHESIS: The purpose of this study was to estimate the efficacy of superselective arterial chemoradiotherapy for locally advanced carcinomas of the external auditory canal and middle ear.
STUDY DESIGN: A retrospective study of clinical data for consecutive patients with locally advanced carcinomas of the external auditory canal and middle ear.
METHODS: Thirteen patients with locally advanced carcinomas of the external auditory canal and middle ear (T3: one patient, T4: 12 patients) were reviewed. The median follow-up duration in the living patients was 33 months. The total dose of radiation therapy was 60 Gy using conventional fractionation. Four, five, or six courses of a superselective arterial infusion (cisplatin 50 mg) were given weekly.
RESULTS: The overall survival and progression-free survival rates at 2 years, calculated by the Kaplan-Meier method, were 58.7% and 53.8%, respectively. No late-phase adverse effects due to chemoradiation and no adverse effects due to catheterization were observed.
CONCLUSIONS: These results suggest that superselective arterial chemoradiation can be a treatment option for locally advanced carcinomas of the external auditory canal and middle ear.
STUDY DESIGN: A retrospective study of clinical data for consecutive patients with locally advanced carcinomas of the external auditory canal and middle ear.
METHODS: Thirteen patients with locally advanced carcinomas of the external auditory canal and middle ear (T3: one patient, T4: 12 patients) were reviewed. The median follow-up duration in the living patients was 33 months. The total dose of radiation therapy was 60 Gy using conventional fractionation. Four, five, or six courses of a superselective arterial infusion (cisplatin 50 mg) were given weekly.
RESULTS: The overall survival and progression-free survival rates at 2 years, calculated by the Kaplan-Meier method, were 58.7% and 53.8%, respectively. No late-phase adverse effects due to chemoradiation and no adverse effects due to catheterization were observed.
CONCLUSIONS: These results suggest that superselective arterial chemoradiation can be a treatment option for locally advanced carcinomas of the external auditory canal and middle ear.